About mitapivat
Pyruvate kinase activator
Used for
- Treats hemolytic anemia in adults with pyruvate kinase deficiency.
Usual adult dose
Usual starting dose: 5 mg by mouth twice daily; the dose is increased gradually, up to 50 mg twice daily.
Common side effects
- Difficulty sleeping
- Headache
- Nausea
- Increased liver enzymes
Important warnings
- Stopping suddenly can cause worsening anemia; taper under medical supervision.
- Liver injury has occurred; liver blood tests are required before and during treatment.
- Can cause fetal harm; effective contraception is recommended during treatment and for six months afterward.
- Dose changes may be needed with certain medicines that affect drug-metabolizing enzymes.
Pregnancy
May cause fetal harm. Human pregnancy data are limited; effective contraception is recommended during treatment and for six months afterward.
Breastfeeding
Unknown whether mitapivat passes into breast milk. Breastfeeding is not recommended during treatment and for three months after the last dose.
Interactions
- Strong CYP3A inhibitors can increase mitapivat levels.
- Strong CYP3A inducers can reduce mitapivat levels.
- Mitapivat can reduce levels of some CYP3A substrates, including hormonal contraceptives.
- Mitapivat can affect levels of medicines metabolized by CYP2B6 or CYP2C substrates.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.